Tags

Type your tag names separated by a space and hit enter

Evening primrose oil and borage oil in rheumatologic conditions.
Am J Clin Nutr 2000; 71(1 Suppl):352S-6SAJ

Abstract

Diets rich in arachidonic acid (20:4n-6) lead to the formation of 2-series prostaglandins (PGs) and 4-series leukotrienes (LTs), with proinflammatory effects. Nonsteroidal antiinflammatory drugs are used in rheumatoid arthritis to inhibit cyclooxygenase (prostaglandin-endoperoxide synthase), thereby decreasing production of 2-series PGs. Lipoxygenase activity remains intact, however, allowing LT production (eg, synthesis of LTB(4), a potent inflammatory mediator) to continue. Altering the essential fatty acid (EFA) content of the diet can modify some of these effects. Ingestion of a diet rich in evening primrose oil elevates concentrations of dihomo-gamma-linolenic acid (DGLA; 20:3n-6), which results in the production of 1-series PGs, eg, PGE(1). DGLA itself cannot be converted to LTs but can form a 15-hydroxyl derivative that blocks the transformation of arachidonic acid to LTs. Increasing DGLA intake may allow DGLA to act as a competitive inhibitor of 2-series PGs and 4-series LTs and thus suppress inflammation. The results of in vitro and animal work evaluating EFAs in inflammatory situations are encouraging, which has stimulated clinical workers to evaluate these compounds in rheumatoid arthritis. Several well-controlled, randomized clinical studies have now been completed in which various EFAs were evaluated as treatments. The results of most of these studies suggest some clinical benefit to these treatments; these data are reviewed here.

Authors+Show Affiliations

Department of Medicine, Ninewells Hospital and Medical School, Dundee, United Kingdom. j.j.f.belch@dundee.ac.ukNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

10617996

Citation

Belch, J J., and A Hill. "Evening Primrose Oil and Borage Oil in Rheumatologic Conditions." The American Journal of Clinical Nutrition, vol. 71, no. 1 Suppl, 2000, 352S-6S.
Belch JJ, Hill A. Evening primrose oil and borage oil in rheumatologic conditions. Am J Clin Nutr. 2000;71(1 Suppl):352S-6S.
Belch, J. J., & Hill, A. (2000). Evening primrose oil and borage oil in rheumatologic conditions. The American Journal of Clinical Nutrition, 71(1 Suppl), 352S-6S. doi:10.1093/ajcn/71.1.352s.
Belch JJ, Hill A. Evening Primrose Oil and Borage Oil in Rheumatologic Conditions. Am J Clin Nutr. 2000;71(1 Suppl):352S-6S. PubMed PMID: 10617996.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evening primrose oil and borage oil in rheumatologic conditions. AU - Belch,J J, AU - Hill,A, PY - 2000/1/5/pubmed PY - 2000/1/5/medline PY - 2000/1/5/entrez SP - 352S EP - 6S JF - The American journal of clinical nutrition JO - Am. J. Clin. Nutr. VL - 71 IS - 1 Suppl N2 - Diets rich in arachidonic acid (20:4n-6) lead to the formation of 2-series prostaglandins (PGs) and 4-series leukotrienes (LTs), with proinflammatory effects. Nonsteroidal antiinflammatory drugs are used in rheumatoid arthritis to inhibit cyclooxygenase (prostaglandin-endoperoxide synthase), thereby decreasing production of 2-series PGs. Lipoxygenase activity remains intact, however, allowing LT production (eg, synthesis of LTB(4), a potent inflammatory mediator) to continue. Altering the essential fatty acid (EFA) content of the diet can modify some of these effects. Ingestion of a diet rich in evening primrose oil elevates concentrations of dihomo-gamma-linolenic acid (DGLA; 20:3n-6), which results in the production of 1-series PGs, eg, PGE(1). DGLA itself cannot be converted to LTs but can form a 15-hydroxyl derivative that blocks the transformation of arachidonic acid to LTs. Increasing DGLA intake may allow DGLA to act as a competitive inhibitor of 2-series PGs and 4-series LTs and thus suppress inflammation. The results of in vitro and animal work evaluating EFAs in inflammatory situations are encouraging, which has stimulated clinical workers to evaluate these compounds in rheumatoid arthritis. Several well-controlled, randomized clinical studies have now been completed in which various EFAs were evaluated as treatments. The results of most of these studies suggest some clinical benefit to these treatments; these data are reviewed here. SN - 0002-9165 UR - https://www.unboundmedicine.com/medline/citation/10617996/Evening_primrose_oil_and_borage_oil_in_rheumatologic_conditions_ L2 - https://academic.oup.com/ajcn/article-lookup/doi/10.1093/ajcn/71.1.352s DB - PRIME DP - Unbound Medicine ER -